key: cord-0928343-vrdrkhzu
authors: Chandra, Samarth
title: Evolution of a 7-mutant strain of SARS-CoV-2 within an immunocompromised person may elucidate the mechanism for the generation of new variants
date: 2022-03-07
journal: J Infect Dis
DOI: 10.1093/infdis/jiac083
sha: 54603038dfcbe5a11ebd6c07d070451b0f85e6eb
doc_id: 928343
cord_uid: vrdrkhzu

nan

M a n u s c r i p t 2 With reference to Tarhini et al [1] , the 7-mutation strain of SARS-CoV-2 is not a nosocomial superinfection, as claimed by the authors, but may have evolved within patient 3. The data on the 7-mutation strain are clinically valuable and provide insights into the mechanism of generation of new variants of the virus.

Based on symptom relapse, the authors claim that the 7-mutation strain is a newly acquired infection as opposed to evolving within the patient. On the contrary, the timing of the symptom relapse rules out superinfection as the origin of the new strain.

Symptom relapse happened on day 73 when these seven mutations were absent.

These seven mutations appeared only in the day 84 sequence. Symptom relapse is explained simply by the immunosuppressive corticosteroid treatment given from day 66 to day 73. Immunosuppression led to viral replication and symptom relapse. The effects of corticosteroid treatment persisted for several weeks after it was over, with viral load on day 84 even higher than day 73 and symptoms gradually resolving over four weeks.

SARS-CoV2 is known to evolve in immunosuppressed persons. New mutants are often detected in immunocompromised persons in the days after a significant disturbance to the immune system [2] [3] [4] [5] [6] . In the changed immune environment, in this case due to immunosuppression, the virus evolved to acquire the seven additional mutations. The authors use the absence of viral evolution in other patients to justify the hypothesis of nosocomial infection as opposed to evolution within the host. But evolves very fast [7, 8] , the time frame being consistent with the emergence of the 7mutation strain.

Further, the frequencies of the seven mutations cannot be considered close to 70%, as claimed. There is a wide spread of frequencies from 65% to 84%. In principle, the error estimates could be this large, but this is fully consistent with the 7-mutation strain coexisting with smaller subpopulations, each with a subset of these seven 

Samarth Chandra holds shares in Spinor Research Labs Private Limited.

This work was supported by Spinor Research Labs Private Limited through grant number Intramural03.

This information has not been presented anywhere else.

A c c e p t e d M a n u s c r i p t

Long-Term Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectiousness Among Three Immunocompromised Patients: From Prolonged Viral Shedding to SARS

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

SARS-CoV-2 evolution during treatment of chronic infection

Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment

Intractable COVID-19 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells (2021)

A c c e p t e d M a n u s c r i p t 6